FDA’s Hamburg touts rising approval record and promises swifter interaction

John Carroll

Margaret , the head of the FDA, turned up at Reuters Health Summit with a bullish assessment of both the agency's responsiveness as well as the biopharma industry's improving track on R&D and new approvals. And she's promising that a new "breakthrough" drug program has the potential to shave three to 5 years off the development process.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS